Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $19.8500 (-1.93%) ($19.8000 - $20.4600) on Thu. Aug. 20, 2015. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.73% (three month average) | RSI | 1 | Latest Price | $19.8500(-1.93%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -2.2% a day on average for past five trading days. | Weekly Trend | ADMS declines -7.6% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(34%) IBB(32%) IWM(22%) XOP(21%) XLV(20%) | Factors Impacting ADMS price | ADMS will decline at least -1.865% in a week (0% probabilities). VIXM(-15%) BNDX(-10%) TLT(-8%) SHY(-7%) UUP(-5%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.865% (StdDev 3.73%) | Hourly BBV | 0 () | Intraday Trend | -1% | | | |
|
1 - 5 Day Possible Target | $5.48(-72.39%) | Resistance Level | $23.56 | 5 Day Moving Average | $20.97(-5.34%) | 10 Day Moving Average | $22.03(-9.9%) | 20 Day Moving Average | $23.56(-15.75%) | To recent high | -33.4% | To recent low | 13.9% | Market Cap | $561m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |